UP!

FMS $22.81

FMS target price
22.81
0
0
Fresenius Medical Care AG & Co. KGaA
Type
Kommanditgesellschaft auf Aktien with Aktiengesellschaft as partner with unlimited liability
Traded as FWB: FME
NYSE: FMS
Industry Health care
Founded 1996
Headquarters Bad Homburg, Germany
Key people
Rice Powell (CEO and Chairman of the executive board), Michael Brosnan (CFO), Roberto Fusté (Chief Executive Officer for Asia-Pacific), Dr. Emanuele Gatti (Chief Executive Officer for Europe, Middle East, Africa and Latin America), Ronald Kuerbitz (Chief Executive Officer for North America), Gerd Krick (Chairman of the supervisory board)
Products Kidney dialysis products and services, Therapuetic Aphoresis Products
Revenue US $14.6 billion (2013)
Operating income
US $2,256 million (2013)
Profit US $1,110 million (2013)
Total assets US $22.120 billion (end 2013)
Total equity US $9.485 billion (end 2013)
Number of employees
90,690 (FTE, end 2013)
Website www.freseniusmedicalcare.com

Fresenius Medical Care is a German company specializing in the production of medical supplies, primarily to facilitate or aid renal dialysis. It is 30% owned by the health care company Fresenius. As of December 31, 2015, the number of Fresenius Medical Care shares held by its largest shareholder, Fresenius SE & Co. KGaA remained unchanged at around 94.4 M. This corresponds to a 30.9% interest in its share capital.

Fresenius Medical Care operates more than 40 production sites on all continents. Its largest plants in terms of production output are in the U.S. (Ogden, Utah, and Concord, California), Germany (Schweinfurt and St. Wendel), and Japan (Buzen). These plants are categorized as large and small with 25 large facilities and 15 small ones worldwide which cater to local demand for dialysis products. Plants that fall under the concentrates division, manufacture finished products from raw materials, such as sodium chloride, dextrose, and magnesium, to name a few. Raw materials go through a complex mixing and packaging process.

Fresenius Medical Care manufactures a variety of durable medical devices used in the treatment of End Stage Renal Disease (ESRD). Devices include Hemodialysis Machines, Peritoneal Dialysis Machines, Granuflo Concentrate Mixing Tanks and monitoring devices including the Crit-line device. The dialysis machines are manufactured in one of two plants to serve the globe. These plants are located in Schweinfurt, Germany and Concord, California. Crit-line devices are manufactured in Concord, California.

Distribution is where the finished product, from Manufacturing, comes in on Semi-Trucks to be distributed to dialysis clinics, hospitals, and home dialysis patients. These products are then used in the dialysis process.

On 30 October 2006, the manufacturing facility (Fresenius Hemocare) in Redmond, Washington was shut down. Fresenius Hemocare has stopped going by the name Fresenius Hemocare and now goes by the name Fresenius-Kabi LLC. The closing of one of two entities inside of Hemocare allowed for the name change and takes Hemocare from the Medical Care group to the Kabi group.

In 2012, Fresenius acquired Liberty Dialysis Holdings, in a deal which entailed the sale of its outpatient dialysis clinics in 43 local markets within the U.S.

In 2013, Fresenius Medical Care NA acquired Shiel Medical Laboratory Inc, expanding services to New York City metro area.

Fresenius Medical Care Renal Services Limited runs 54 dialysis units across England and more across Wales. In September 2014 new renal dialysis units run by Fresenius were opened at Withybush General Hospital and West Wales General Hospital, with a contract to run for at least 7 years.

In August 2017, Fresenius acquired NxStage Medical, a medical device manufacturer based in Lawrence, Massachusetts for a reported $2 billion dollars.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2022 2022-11-01 Future report Set alerts
Q2 2022 2022-08-02 Future report Set alerts
Q1 2022 2022-05-04 0.34 0.34
Q4 2021 2022-02-22 0.00 0.00
Q3 2021 2021-11-02 0.00 0.00
Q2 2021 2021-07-30 0.38 0.38
Q1 2021 2021-05-06 0.00 0.00
Q4 2020 2021-02-23 0.64 0.64
Q3 2020 2020-10-29 0.00 0.00
Q2 2020 2020-07-30 0.60 0.68

Ratings

2016-07-08 Upgrade Jefferies Group Underperform to Hold
2016-05-24 Reiterated Rating RBC Capital Hold
2016-05-24 Reiterated Rating Royal Bank Of Canada Hold
2016-05-16 Reiterated Rating Robert W. Baird Hold
2016-05-10 Reiterated Rating DZ Bank AG Sell
2016-04-11 Initiated Coverage Sanford C. Bernstein Outperform
2016-03-17 Initiated Coverage Nomura Buy
2016-03-17 Initiated Coverage Nomura Holdings Inc. Buy
2016-03-04 Reiterated Rating DZ Bank AG Sell
2016-02-13 Upgrade Berenberg Bank Buy
2016-01-26 Reiterated Rating Nord/LB Buy
2016-01-04 Upgrade JPMorgan Chase & Co. Neutral to Overweight
2015-11-24 Reiterated Rating Goldman Sachs Buy
2015-11-24 Reiterated Rating Goldman Sachs Group Inc. Buy
2015-11-09 Downgrade Barclays Equal Weight to Underweight
2015-11-09 Downgrade Barclays PLC Equal Weight to Underweight
2015-11-04 Boost Price Target RBC Capital Sector Perform $40.00 to $42.00
2015-10-30 Reiterated Rating Piper Jaffray Hold $41.00 to $43.00
2015-10-30 Reiterated Rating Piper Jaffray Cos. Hold $41.00 to $43.00
2015-10-29 Reiterated Rating DZ Bank AG Sell
2015-09-22 Reiterated Rating Goldman Sachs Buy
2015-09-15 Reiterated Rating Goldman Sachs Buy
2015-09-03 Upgrade Goldman Sachs Neutral to Buy
2015-08-13 Downgrade Societe Generale Buy to Hold
2015-07-31 Boost Price Target RBC Capital Sector Perform $35.00 to $40.00
2015-05-29 Downgrade Commerzbank AG Hold
2015-02-27 Upgrade HSBC Underweight to Neutral
2015-01-21 Downgrade Barclays Overweight to Equal Weight
2014-12-18 Downgrade Bryan Garnier & Cie Neutral
2014-12-18 Downgrade Bryan, Garnier & Co Neutral
2014-12-15 Initiated Coverage Dundee Securities Buy
2014-11-28 Downgrade Morgan Stanley Overweight to Equal Weight
2014-10-24 Upgrade Berenberg Bank Hold to Buy
2014-10-10 Upgrade Bank of America Neutral to Buy
2014-10-10 Upgrade Bank of America Corp. Neutral to Buy
2014-09-16 Boost Price Target Sanford C. Bernstein $40.50 to $42.20
2014-08-11 Upgrade Societe Generale Hold to Buy
2014-08-01 Boost Price Target Piper Jaffray $33.00 to $34.00
2014-06-30 Downgrade Jefferies Group Hold to Underperform
2014-06-26 Upgrade Credit Suisse Neutral to Outperform
2014-05-12 Lower Price Target Piper Jaffray $34.00 to $33.00
2014-03-05 Downgrade Berenberg Bank Buy to Hold
2014-03-04 Downgrade HSBC Neutral to Underweight
2014-01-08 Upgrade JPMorgan Chase & Co. Underweight to Neutral
2013-12-02 Upgrade Morgan Stanley Equal Weight to Overweight
2013-09-27 Downgrade Deutsche Bank Hold to Sell $44.00
2013-01-14 Upgrade HSBC Securities Neutral to Overweight
2012-10-11 Downgrade HSBC Securities Overweight to Neutral
2012-08-02 Downgrade HSBC Securities Overweight to Neutral
2010-02-25 Downgrade Piper Jaffray Overweight to Neutral
2010-02-09 Initiated Jefferies & Co Buy
2009-08-19 Initiated Stifel Nicolaus Hold $44
2009-06-25 Initiated Sun Trust Rbsn Humphrey Buy $51
2009-04-16 Reiterated RBC Capital Mkts Outperform $59 to $56
2008-11-17 Downgrade Deutsche Securities Buy to Hold
2008-10-13 Upgrade UBS Neutral to Buy
2008-07-11 Downgrade Wachovia Outperform to Mkt Perform
2016-07-08 Upgrade Jefferies Group Underperform to Hold
2016-05-24 Reiterated Rating RBC Capital Hold
2016-05-24 Reiterated Rating Royal Bank Of Canada Hold
2016-05-16 Reiterated Rating Robert W. Baird Hold
2016-05-10 Reiterated Rating DZ Bank AG Sell

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks